In vivo IL-10 gene delivery suppresses airway eosinophilia and hyperreactivity by down-regulating APC functions and migration without impairing the antigen-specific systemic immune response in a mouse model of allergic airway inflammation

被引:59
作者
Nakagome, K
Dohi, M
Okunishi, K
Komagata, Y
Nagatani, K
Tanaka, R
Miyazaki, J
Yamamoto, K
机构
[1] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Bunkyo Ku, Tokyo 1138655, Japan
[2] Osaka Univ, Grad Sch Med, Div Stem Cell Regulat Res, Osaka, Japan
关键词
D O I
10.4049/jimmunol.174.11.6955
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
IL-10 is an inummostappressive cytokine. Although previous studies have reported that exogenous delivery of IL-10 reduced airway inflammation in experimental allergic airway inflammation, the mechanism of action has not been fully clarified. In this report, we elucidated a mechanism of action of IL-10 in vivo. BALM mice were immunized and aerosol challenged with OVA-Ag. We delivered the IL-10 gene to the mice before systemic sensitization or during aerosol Ag challenge by administering an IL-10-producing plasmid vector. Not only presensitization delivery of IL-10, as reported, but also delivery during inflammation strongly suppressed the development of airway eosinophilia and hyperreactivity. Presensitization delivery suppressed the Ag-specific Th2-type immune response in both the lung and spleen. In contrast, delivery in the effector phase suppressed the Th2 response only in the lung, whereas that in the spleen was not affected. IL-10 gene delivery did not induce the development of a regulatory phenotype of T cells or dendritic cells; rather, it suppressed the overall functions of CD11c(+) APCs of the lung such as Ag-presenting capacity, cytokine production, and transportation of OVA-Ag to lymph nodes, thus attenuating Th2-mediated allergic airway inflammation. Further, IL-10 revealed a distinct immunosuppressive effect in the presence of Ag and APCs. These results suggest that suppression of APC function in the lung, the site of immune response, played a critical role in the IL-10-mediated suppression of Ag-induced airway inflammation and hyperreactivity. Therefore, if delivered selectively, IL-10 could site specifically suppress the Ag-specific immune response without affecting systemic immune responses.
引用
收藏
页码:6955 / 6966
页数:12
相关论文
共 57 条
[1]
Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen [J].
Akbari, O ;
DeKruyff, RH ;
Umetsu, DT .
NATURE IMMUNOLOGY, 2001, 2 (08) :725-731
[2]
Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745
[3]
Role of interleukin 10 in specific immunotherapy [J].
Akdis, CA ;
Blesken, T ;
Akdis, M ;
Wüthrich, B ;
Blaser, K .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (01) :98-106
[4]
Mechanisms of allergen-specific immunotherapy [J].
Akdis, CA ;
Blaser, K .
ALLERGY, 2000, 55 (06) :522-530
[5]
Interleukin-10 therapy - Review of a new approach [J].
Asadullah, K ;
Sterry, W ;
Volk, HD .
PHARMACOLOGICAL REVIEWS, 2003, 55 (02) :241-269
[6]
IL-10 is a key cytokine in psoriasis -: Proof of principle by IL-10 therapy:: A new therapeutic approach [J].
Asadullah, K ;
Sterry, W ;
Stephanek, K ;
Jasulaitis, D ;
Leupold, M ;
Audring, H ;
Volk, HD ;
Döcke, WD .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :783-794
[7]
Effects of systemic interleukin-10 therapy on psoriatic skin lesions:: Histologic, immunohistologic, and molecular biology findings [J].
Asadullah, K ;
Friedrich, M ;
Hanneken, S ;
Rohrbach, C ;
Audring, H ;
Vergopoulos, A ;
Ebeling, M ;
Döcke, WD ;
Volk, HD ;
Sterry, W .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 116 (05) :721-727
[8]
Interleukin 10 treatment of psoriasis -: Clinical results of a phase 2 trial [J].
Asadullah, K ;
Döcke, WD ;
Ebeling, M ;
Friedrich, M ;
Belbe, G ;
Audring, H ;
Volk, HD ;
Sterry, W .
ARCHIVES OF DERMATOLOGY, 1999, 135 (02) :187-192
[9]
Interleukin 10 gene transfer prevents experimental colitis in rats [J].
Barbara, G ;
Xing, Z ;
Hogaboam, CM ;
Gauldie, J ;
Collins, SM .
GUT, 2000, 46 (03) :344-349
[10]
BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295